Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078371 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1CYP1A2CYP2C19PKM | |
| SCHEMBL119909 | 0.83 | LMNA (0.77) | SMN1; SMN2CA12CA9ALDH1A1LMNA | |
| SCHEMBL31113449 | 0.83 | ALDH1A1 (0.74) | SMN1; SMN2ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL5167263 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2CA12CA9ALDH1A1LMNA | |
| SCHEMBL5892016 | 0.82 | CYP19A1 (0.57) | SMN1; SMN2ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL5960118 | 0.82 | ALDH1A1 (0.76) | SMN1; SMN2ALDH1A1L3MBTL1GLAMAPT | |
| SCHEMBL9460384 | 0.80 | CA12 (0.67) | CA12CA9LMNACYP1A2CYP2C19 | |
| SCHEMBL5163986 | 0.80 | MEN1 (0.52) | SMN1; SMN2ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL30733139 | 0.80 | MEN1 (0.52) | SMN1; SMN2ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL5164007 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2CA12CA9ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | SMN1; SMN2 3478/4885CA12 4195/4885CA9 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.